HYDELTRA-TBA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYDELTRA-TBA (HYDELTRA-TBA).
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
| Metabolism | Hepatic; primarily via 11β-hydroxysteroid dehydrogenase (HSD11B) and 5α/5β-reductase; also metabolized by CYP3A4 in some contexts. |
| Excretion | Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%. |
| Half-life | Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours. |
| Protein binding | 70-80% bound primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd ~0.5-1.0 L/kg. Distributes widely into tissues, including synovial fluid. |
| Bioavailability | Oral: 60-70% (variable due to first-pass metabolism); IM: 100%. |
| Onset of Action | IM: 1-2 hours; IV: rapid (minutes); Oral: 1-2 hours. |
| Duration of Action | IM: 4-8 days (repository formulation); Oral: 24-36 hours; IV: 6-12 hours. |
| Molecular Weight | 360.44 |
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment due to potential fluid retention and hypertension. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: consider dose reduction by 50%; Child-Pugh C: avoid use or use lowest possible dose with close monitoring. |
| Pediatric use | 0.5-2 mg/kg/day intramuscularly divided every 12-24 hours; maximum 40 mg/day. |
| Geriatric use | Use lowest effective dose; monitor for hyperglycemia, osteoporosis, and fluid retention; consider reduced initial dose due to increased sensitivity. |
| 1st trimester | Corticosteroids are associated with increased risk of cleft palate (2–5 per 1000 births) when used during first trimester. Benefit may outweigh risk for serious maternal conditions. |
| 2nd trimester | May cause fetal adrenal suppression with prolonged use. Use only if clearly needed for maternal condition. |
| 3rd trimester | Monitor for signs of adrenal insufficiency in neonates if used near term. Risk of intrauterine growth restriction with prolonged use. |
Clinical note
Comprehensive clinical and safety monograph for HYDELTRA-TBA (HYDELTRA-TBA).
| Placental transfer | Prednisolone (active form) crosses placenta, but is largely inactivated by placental 11β-hydroxysteroid dehydrogenase type 2; however, with high maternal doses, significant transfer can occur, potentially leading to fetal adrenal suppression. |
| Breastfeeding | Small amounts of prednisolone (the active metabolite) are excreted into breast milk, but no adverse effects reported in term infants. With maternal doses up to 40 mg/day, nursing infant exposure is low (<10% of maternal dose). Consider timing breastfeeding 4 hours after dose or using lowest effective dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionsKnown hypersensitivity to prednisolone or any componentAdministration of live or live-attenuated vaccines in patients receiving immunosuppressive dosesIdiopathic thrombocytopenic purpura (relative contraindication for intramuscular use due to hematoma risk)
| Precautions | Immunosuppression and increased susceptibility to infections, Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use, Osteoporosis risk with long-term therapy, Gastrointestinal perforation (especially in IBD), Exacerbation of systemic fungal infections, Live or live attenuated vaccines contraindicated in immunosuppressed patients, May cause posterior subcapsular cataracts and glaucoma, Psychiatric disturbances (e.g., euphoria, psychosis) |
| Food/Dietary | Avoid grapefruit and grapefruit juice as it may increase drug levels. Limit sodium and high-sugar foods to manage fluid retention and hyperglycemia. Increase potassium intake (bananas, oranges) if hypokalemia occurs. |
Loading safety data…
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | Prednisolone (active metabolite of prednisone) crosses the placenta. First trimester: increased risk of oral clefts (odds ratio 3.4). Second/third trimester: associated with fetal growth restriction, preterm birth, and maternal hypertension. Chronic use may cause fetal adrenal suppression. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (gestational diabetes), and fetal growth via ultrasound. Assess for signs of preterm labor. Newborn monitoring for adrenal insufficiency if maternal use continues until delivery. |
| Fertility Effects | High doses may disrupt menstrual cycles and ovulation. No known permanent impairment; effects are reversible upon dose reduction or discontinuation. |
| Clinical Pearls | Hydeltra-TBA (prednisolone acetate) is a corticosteroid used for its anti-inflammatory and immunosuppressive effects. Monitor for signs of adrenal insufficiency during taper. Avoid abrupt discontinuation after prolonged use. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease. Consider Pneumocystis jirovecii prophylaxis in prolonged high-dose therapy. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without medical advice. · May cause increased appetite, weight gain, insomnia, or mood changes. · Report any unusual bleeding, vision changes, or signs of infection (fever, sore throat). · Avoid live vaccines during treatment. · Carry a steroid warning card if on long-term therapy. · Take with food to reduce GI upset. |